“It is sometimes easy to forget that academic research can change the world," said James Frederich, the Werner Herz Associate Professor in @fsuchemistry. "Daraxonrasib, and the mechanism underlying its action, serves as an excellent reminder of the long-term return on investing in academic science.” Daraxonrasib — a promising new pancreatic cancer drug that nearly doubled survival times in a recent clinical trial — is a prominent example of how breakthroughs found in university laboratories help lay the foundation for life-changing collaborations between university researchers and biotech companies. With research specialties spanning chemical biology, synthesis and catalysis, Frederich is available for interviews on the role of universities in developing cancer-treating drugs. For more information, tap 'News' at the #linkinbio.